Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.35 |
| ▸ | PRNP | P04156 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1803333 | 0.74 | ALDH1A1 (0.39) | ADORA1ADORA3NOTUMALDH1A1KMT2A | |
| SCHEMBL3626705 | 0.72 | NOTUM (0.37) | ADORA1ADORA3NOTUMKMT2AMEN1 | |
| SCHEMBL13078703 | 0.70 | MAPT (0.52) | ADORA1ADORA3NOTUMALDH1A1KMT2A | |
| SCHEMBL13078708 | 0.70 | ADORA1 (0.51) | ADORA1ADORA3NOTUMALDH1A1KMT2A | |
| SCHEMBL1907314 | 0.70 | NOTUM (0.40) | NOTUMKMT2AMEN1MGLL | |
| SCHEMBL16202020 | 0.69 | ADORA1 (0.47) | ADORA1ADORA3NOTUMALDH1A1KMT2A | |
| SCHEMBL30725595 | 0.69 | ADORA1 (0.47) | ADORA1ADORA3NOTUMALDH1A1KMT2A | |
| SCHEMBL2902914 | 0.68 | NOTUM (0.41) | ADORA1ADORA3NOTUMALDH1A1KMT2A | |
| SCHEMBL1898960 | 0.68 | ADORA1 (0.42) | ADORA1ADORA3NOTUMKMT2AMEN1 | |
| SCHEMBL1907377 | 0.68 | SMN1; SMN2 (0.44) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455477-B2 | Therapeutic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110207711-A1 | Therapeutic Compounds | MSD K.K. (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2320907-A1 | THERAPEUTIC COMPOUNDS | Merck & Co., Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010017047-A1 | THERAPEUTIC COMPOUNDS | MERCK & CO., INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207711-A1 | Therapeutic Compounds | WEE2, MARK3, WEE1 | ADORA1 4077/4885ADORA3 2968/4885NOTUM 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.